Loading...
XNAS
IART
Market cap961mUSD
Jul 30, Last price  
12.37USD
1D
-3.81%
1Q
-24.76%
Jan 2017
-71.17%
Name

Integra Lifesciences Holdings Corp

Chart & Performance

D1W1MN
P/E
P/S
0.60
EPS
Div Yield, %
Shrs. gr., 5y
-2.30%
Rev. gr., 5y
1.20%
Revenues
1.61b
+4.47%
277,935,000419,297,000550,459,000654,604,000682,487,000732,068,000780,078,000830,871,000836,214,000928,305,000882,734,000992,075,0001,188,236,0001,472,441,0001,517,557,0001,371,868,0001,542,448,0001,557,666,0001,541,573,0001,610,527,000
Net income
-7m
L
37,194,00029,407,00033,471,00034,933,00050,955,00065,669,00027,989,00041,204,000-16,977,00034,004,000-3,519,00074,564,00064,743,00060,801,00050,201,000133,892,000169,075,000180,550,00067,741,000-6,944,000
CFO
129m
-7.55%
56,848,00071,702,00047,026,00072,590,000143,235,000105,571,000104,328,00058,715,00053,268,00079,463,00094,483,000116,405,000114,544,000199,683,000373,682,000203,832,000312,427,000264,469,000139,955,000129,382,000

Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
IPO date
Aug 16, 1995
Employees
3,722
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,610,527
4.47%
1,541,573
-1.03%
1,557,666
0.99%
Cost of revenue
843,843
827,772
688,548
Unusual Expense (Income)
NOPBT
766,684
713,801
869,118
NOPBT Margin
47.60%
46.30%
55.80%
Operating Taxes
(11,293)
13,328
33,344
Tax Rate
1.87%
3.84%
NOPAT
777,977
700,473
835,774
Net income
(6,944)
-110.25%
67,741
-62.48%
180,550
6.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
(52,471)
(275,000)
(144,153)
BB yield
3.00%
7.86%
3.08%
Debt
Debt current
62,986
29,815
52,749
Long-term debt
348,400
1,834,000
1,734,654
Deferred revenue
7,700
8,800
Other long-term liabilities
1,342,255
192,240
129,701
Net debt
137,819
1,524,009
763,401
Cash flow
Cash from operating activities
129,382
139,955
264,469
CAPEX
(104,418)
(66,865)
(47,085)
Cash from investing activities
(390,808)
(94,178)
(58,580)
Cash from financing activities
237,863
(229,925)
(251,953)
FCF
1,196,370
628,581
695,776
Balance
Cash
273,567
309,096
456,661
Long term investments
30,710
567,341
Excess cash
193,041
262,727
946,119
Stockholders' equity
913,260
932,662
890,288
Invested Capital
2,949,433
3,206,779
2,667,975
ROIC
25.27%
23.85%
29.42%
ROCE
23.93%
20.37%
24.00%
EV
Common stock shares outstanding
77,010
80,337
83,516
Price
22.68
-47.92%
43.55
-22.33%
56.07
-16.30%
Market cap
1,746,587
-50.08%
3,498,676
-25.29%
4,682,742
-18.23%
EV
1,884,406
5,022,685
5,446,143
EBITDA
907,577
837,313
987,417
EV/EBITDA
2.08
6.00
5.52
Interest
70,632
51,377
49,594
Interest/NOPBT
9.21%
7.20%
5.71%